Arca
Skip to content
Tools
Tools

Label Changes: Penpulimab Kcqx (penpulimab-kcqx)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Penpulimab Kcqx label DailyMed has published, from Akeso Biopharma, Co., Ltd, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 2
  • Sections changed, version 1 to 2: 6

What changed from version 1 to version 2

Apr 30, 2025 to Sep 10, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Dosage and administrationChanged ยท 2 words added, 4 removed
  2. Warnings and precautionsChanged ยท 23 words added
  3. Adverse reactionsChanged ยท 4 words added, 8 removed
  4. Clinical studiesChanged ยท 6 words added, 9 removed
  5. Medication guideChanged ยท 2 words added, 3 removed
  6. Patient counseling informationChanged ยท 1 word added, 1 removed

Dosage and administration

Changed2 words added, 4 removed
7 unchanged lines
penpulimab-kcqx 200 mg intravenously | Every 3 weeks for 6 cycles, and then every 3 weeks until unacceptable toxicity or disease progression for a maximum of 24 months
gemcitabine 1000 mg/m 2 intravenously2intravenously | Every 3 weeks for 6 cycles
cisplatin 80 mg/m 2 intravenously2intravenously or carboplatin AUC 5 intravenously | Every 3 weeks for 6 cycles
2.2 Recommended Dosage of Penpulimab-kcqx as a Single Agent โ€“ Every 2 Week Dosing
45 unchanged lines

Warnings and precautions

Changed23 words added
28 unchanged lines
Thyroid Disorders:
Penpulimab-kcqx can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement therapy for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue penpulimab-kcqx based on the severity [ see Dosage and Administration (2) ] .
Penpulimab-kcqx in Combination with Either Cisplatin or Carboplatin and Gemcitabine
30 unchanged lines
Hematologic/Immune: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection.
Other: Myocarditis-Myositis-Myasthenia Gravis (or Myasthenia-Like) Overlap Syndrome, reported as the co-occurrence of either two or all three adverse reactions.
5.2 Infusion-Related Reactions
11 unchanged lines

Adverse reactions

Changed4 words added, 8 removed
1 unchanged line
The following adverse reactions are described in other sections of the labeling:
Severe and Fatal Immune-Mediated Adverse Reactions [see Warnings and Precautions (5.1) ]
Infusion-Related Reactions[see Warnings and Precautions (5.2) ]
Complications of Allogeneic HSCT [see Warnings and Precautions (5.3)]
1 unchanged line
Because clinical trials are conducted under varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to those observed in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described in the WARNINGS AND PRECAUTIONS reflect exposure to penpulimab-kcqx in 146 patients in Study AK105-304 [see Clinical Studies (14.1) ]. Patients received 6 cycles every 3 weeks of intravenous penpulimab-kcqx 200 mg in combination with either cisplatin 80 mg/m 2 or2or carboplatin AUC 5 and gemcitabine 1000 mg/m 2 followed2followed by single-agent penpulimab-kcqx 200 mg every 3 weeks until disease progression or a maximum of 24 months. Among the 146 patients who received penpulimab-kcqx in combination with either cisplatin or carboplatin and gemcitabine, 71% were exposed for 6 months or longer and 38% were exposed for greater than one year. In this safety population, the most common (โ‰ฅ 20%) adverse reactions were nausea (58%), vomiting (55%), hypothyroidism (45%), constipation (41%), decreased appetite (36%), decreased weight (26%), cough (25%), COVID-19 infection (25%), fatigue (25%), rash (24%) and pyrexia (21%). The most common Grade 3 to 4 laboratory abnormalities (โ‰ฅ 2%) were decreased lymphocytes (70%), decreased neutrophils (61%), decreased white blood cells (58%), decreased hemoglobin (49%), decreased platelets (33%), decreased potassium (14%), increased lipase (11%), increased ALT (8%), decreased sodium (7%), increased AST (6%), increased triglycerides (4.3%), decreased magnesium (4.2%), decreased CPK (4.1%), increased amylase (2.9%), increased potassium (2.8%), increased cholesterol (2.2%), increased calcium (2.1%) and increased blood bilirubin (2.1%).
The data described in the WARNINGS AND PRECAUTIONS also reflect exposure to single-agent intravenous penpulimab-kcqx 200 mg every 2 weeks until disease progression or a maximum of 24 months in 372 patients in studies: AK105-101 [NCT03352531], AK-105-201 [NCT03722147], AK105-202 [see Clinical Studies (14.2)], AK105-204 [NCT 04172506]. Among the 372 patients who received single-agent penpulimab-kcqx, 49% were exposed for 6 months or longer and 34% were exposed for at least one year. In this safety population, the most common (โ‰ฅ20%) adverse reactions were anemia (25%) and hypothyroidism (23%). The most common Grade 3 to 4 laboratory abnormalities (โ‰ฅ 2%) were decreased lymphocytes (11%), increased GGT (9%), decreased phosphate (6%), decreased sodium (4.7%), increased aspartate aminotransferase (4.4%), increased alkaline phosphatase (4%), decreased hemoglobin (3.6%), increased bilirubin (2.7%), increased glucose (3%), increased triglycerides (2.8%), increased alanine aminotransferase (2.5%), increased magnesium (3.3%), and decreased platelets (2.5%).
129 unchanged lines
Hemoglobin decreased | 36 | 4.7
1 Toxicity1Toxicity graded according to NCI CTCAE v5.0. 2 Each2Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: penpulimab-kcqx (range of the patient number: 128 to130).

Clinical studies

Changed6 words added, 9 removed
13 unchanged lines
Table 7 Efficacy Results in AK105-304
Endpoint | Penpulimab-kcqx cisplatin or carboplatin and gemcitabine NgemcitabineN=144 | Placebo cisplatin or carboplatin and gemcitabine NgemcitabineN=147
BICR-assessed Progression-free Survival
BICR-assessedProgression-free Survival
Number of Events n (%) | 80 (56) | 109 (74)
22 unchanged lines

Medication guide

Changed2 words added, 3 removed
28 unchanged lines
shortness of breath or wheezing | back pain
Rejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you depending on the type of organ or tissue transplant that you have had. Complications, including graft-versus-host-disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with penpulimab-kcqx. Your healthcare provider will monitor you for these complications. Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check for these problems during treatment with penpulimab-kcqx. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with penpulimab-kcqx if you have severe side effects.
What is penpulimab-kcqx? Penpulimab-kcqx is a prescription medicine used to treat adults with a kind of cancer called non-keratinizing nasopharyngeal carcinoma (NPC). Penpulimab-kcqx may be used in combination with either the chemotherapy medicines cisplatin or carboplatin and gemcitabine, as your first treatment when your non-keratinizing NPC has returned (recurrent) or has spread to other parts of your body (metastatic). Penpulimab-kcqx may be used alone to treat your non-keratinizing NPC when it: has spread (metastatic), and you received chemotherapy that contains platinum and at least 1 other type of treatment, and it did not work or is no longer working. It is not known if penpulimab-kcqx is safe and effective in children.
Before receiving penpulimab-kcqx, tell your healthcare provider about all of your medical conditions, including if you: have immune system problems such as Crohnโ€™s disease, ulcerative colitis, or lupus have received an organ transplant, including corneal transplant have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic) have received radiation treatment to your chest area have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barrรฉ syndrome are pregnant or plan to become pregnant. Penpulimab-kcqx can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider will give you a pregnancy test before you start treatment with penpulimab-kcqx. You should use an effective method of birth control during your treatment and for 4 months after your last dose of penpulimab-kcqx. Talk to your healthcare provider about birth control methods that you can use during this time. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with penpulimab-kcqx. are breastfeeding or plan to breastfeed. It is not known if penpulimab-kcqx passes into your breast milk. Do not breastfeed during treatment with penpulimab-kcqx and for 4 months after your last dose of penpulimab-kcqx. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will I receive penpulimab-kcqx? Your healthcare provider will give you penpulimab-kcqx into your vein through an intravenous (IV) line over 60 minutes. Penpulimab-kcqx is usually given every 2 or 3 weeks. Your healthcare provider will decide how many treatments you need. Your healthcare provider will test your blood to check you for certain side effects. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.
4 unchanged lines
constipation | COVID-19 infection |
The most common side effects of penpulimab-kcqx when used alone include lowincludelow red blood cell count (anemia) and low thyroid hormone levels. These are not all the possible side effects of penpulimab-kcqx. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of penpulimab-kcqx. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about penpulimab-kcqx that is written for healthcare professionals.
What are the ingredients in penpulimab-kcqx? Active ingredient: penpulimab-kcqx Inactive ingredients: acetic acid, polysorbate 80, sodium acetate, sorbitol, and Water for Injection. Manufactured by: Akeso Biopharma Co., Ltd., 6 Shennong Road, Torch Development Zone, Zhongshan, Guangdong 528437, China U.S. License No. xxxx2253 For more information, call 833-662-5376 or go to https://www.akesobio.com/en/.
This Medication Guide has been approved by the U.S. Food and Drug Administration. Issued: April/2025

Patient counseling information

Changed1 word added, 1 removed
24 unchanged lines
6 Shennong Road, Torch Development Zone, Zhongshan, Guangdong 528437, China
U.S. license number xxxx2253

Unchanged: Indications and usage, Dosage forms and strengths, Contraindications, Use in specific populations, Description, Clinical pharmacology, Nonclinical toxicology, How supplied.

Every version

2 versions of set 830004e8-31af-4cc6-ab16-e870cab1c5ca, newest first.
VersionPublished on DailyMedCompareSPL file
2Sep 10, 2026Shown belowDownload .zip
1Apr 30, 2025First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.